A Multinational Pharmacoeconomic Evaluation of Acute Major Depressive Disorder (MDD): a Comparison of Cost-Effectiveness Between Venlafaxine, SSRIs and TCAs

Doyle, John; Casciano, Julian; Arikian, Steven R.; Tarride, Jean-Eric; González, Marco; Casciano, Roman

doi:10.1046/j.1524-4733.2001.004001016.x

Cited by 54 publications

(28 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…67 Direct and indirect costs in the United States are estimated to be as high as 80 billion dollars per year. 68 Response rates to conservative management with FDA-approved antidepressants range from 45-55%, and remission rates can be as low as 30%. Although polytherapy may benefit some individuals, electroconvulsive therapy (ECT) has been associated with the highest remission rates.…”

Section: Vagus Nerve Stimulation For Treatment-resistant Depressionmentioning

confidence: 99%

Vagus Nerve Stimulation for Epilepsy and Depression

2008

View full text Add to dashboard Cite

Summary: Many patients with epilepsy suffer from persistent seizures despite maximal antiepileptic drug (AED) therapy. Chronic, intermittent vagus nerve stimulation (VNS) has proven to be a safe, effective option for patients suffering from refractory seizures who are not candidates for surgical resection. Although only a small minority of patients will be entirely seizure-free, VNS as an adjunct to medical therapy does appear to provide a significant amount of improvement in quality of life. Reports of antidepressant effects independent of seizure control, along with the use of multiple AEDs in the treatment of depression, has led to the investigation of VNS as a potential adjunctive treatment for major depressive disorder. Both the number of severely depressed patients refractory to available pharmacologic options and the need for repeated treatments and significant side effects associated with electroconvulsive therapy have heightened the interest in VNS for this patient population. Pilot studies of VNS for depression have shown impressive response rates; however, the effect appears to be gradual in onset, as demonstrated by the lack of a favorable response in a short-term, randomized controlled study. Investigation is thus needed to establish the potential role of VNS as an adjunctive treatment for severe depression.

show abstract

Section: Vagus Nerve Stimulation For Treatment-resistant Depressionmentioning

confidence: 99%

Vagus Nerve Stimulation for Epilepsy and Depression

2008

View full text Add to dashboard Cite

show abstract

“…The majority of these use decisionanalytic techniques and are based on secondary data. 18,[70][71][72][73][74][75][76][77] Only three evaluations collected resource-use and outcome data within the studies, of which two studies collected data prospectively alongside clinical trials. [78][79][80] Of the evaluations using decision-analytic techniques to evaluate the cost-effectiveness of these medications in outpatients or primary care, the majority found in favour of SSRIs.…”

Section: Previous Work On the Costeffectiveness Of Antidepressant Drugsmentioning

confidence: 99%

“…Their results for outpatient settings suggested that SSRIs dominated TCAs in eight countries, including the UK, but produced additional benefit at a cost in two countries. 74 Einarson and colleagues found that SSRIs dominated TCAs when compared in an outpatient setting, but that TCAs dominated SSRIs when compared in an inpatient setting. 76 Results from a study by the Canadian Co-ordinating Office for Health Technology Assessment (CCOHTA) suggested that first line treatment (allowing for switching) with SSRIs produced a QALY gain at an additional cost compared with first line treatment with TCAs.…”

Section: Previous Work On the Costeffectiveness Of Antidepressant Drugsmentioning

confidence: 99%

A randomised controlled trial to compare the cost-effectiveness of tricyclic antidepressants, selective serotonin reuptake inhibitors and lofepramine

Peveler

Kendrick²,

Buxton³

et al. 2005

Health Technol Assess

View full text Add to dashboard Cite

Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is £2 per monograph and for the rest of the world £3 per monograph.You can order HTA monographs from our Despatch Agents:-fax (with credit card or official purchase order) -post (with credit card or official purchase order or cheque) -phone during office hours (credit card only).Additionally the HTA website allows you either to pay securely by credit card or to print out your order and then post or fax it. NHS libraries can subscribe free of charge. Public libraries can subscribe at a very reduced cost of £100 for each volume (normally comprising 30-40 titles). The commercial subscription rate is £300 per volume. Please see our website for details. Subscriptions can only be purchased for the current or forthcoming volume. Contact details are as follows: Payment methods Paying by chequeIf you pay by cheque, the cheque must be in pounds sterling, made payable to Direct Mail Works Ltd and drawn on a bank with a UK address. Paying by credit cardThe following cards are accepted by phone, fax, post or via the website ordering pages: Delta, Eurocard, Mastercard, Solo, Switch and Visa. We advise against sending credit card details in a plain email. Paying by official purchase orderYou can post or fax these, but they must be from public bodies (i.e. NHS or universities) within the UK. We cannot at present accept purchase orders from commercial companies or from outside the UK. How do I get a copy of HTA on CD?Please use the form on the HTA website (www.hta.ac.uk/htacd.htm). Or contact Direct Mail Works (see contact details above) by email, post, fax or phone. HTA on CD is currently free of charge worldwide.The website also provides information about the HTA Programme and lists the membership of the various committees. Health Technology Assessment is indexed and abstracted in NHS R&D HTA ProgrammeT he research findings from the NHS R&D Health Technology Assessment (HTA) Programme directly influence key decision-making bodies such as the National Institute for Health and Clinical Excellence (NICE) and the National Screening Committee (NSC) who rely on HTA outputs to help raise standards of care. HTA findings also help to improve the quality of the service in the NHS indirectly in that they form a key component of the 'National Knowledge Service' that is being developed to improve the evidence of clinical practice throughout the NHS.The HTA Programme was set up in 1993. Its role is to ensure that high-quality research information on the costs, effectiveness and broader impact of health technologies is produced in the most efficient way for those who use, manage and provide care in the NHS. 'Health technologies' are broadly defined to include all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care, rather than settings of care.The HTA programme commissions research only on topics where it has identified key gaps in the evidence needed by the NHS. Suggestions for top...

show abstract

“…In almost all studies, venlafaxine or SNRIs were cost-effective compared to SSRIs and TCAs (9,13,18). A recent Brazilian study concluded that SNRIs, SSRIs, and TCAs had no significant differences in cost-effectiveness results (19).…”

Section: Discussionmentioning

confidence: 99%

“…Most pharmacoeconomic studies on antidepressants have been conducted in Europe and North America, however, with only a few analyses of this type performed in South America (7,8). Only one study (in Venezuela) was found evaluating antidepressants (9). There were three existing pharmacoeconomic studies available in Colombia (7).…”

mentioning

confidence: 99%

Pharmacoeconomics of antidepressants in moderate-to-severe depressive disorder in Colombia

Machado¹,

Lopera²,

Rojas³

et al. 2008

Rev. panam. salud pública

View full text Add to dashboard Cite

Objective. To compare three antidepressant drugs from different classes used in treating moderate-to-severe major depressive disorder (MDD) in Colombian adults. Methods. Based on expert input, a decision-tree model was adapted for ABSTRACTDepression is a major health problem worldwide, ranking fourth globally as a health problem (1, 2). Latin America is no exception, and the problem may be even worse in that part of

show abstract

A Multinational Pharmacoeconomic Evaluation of Acute Major Depressive Disorder (MDD): a Comparison of Cost-Effectiveness Between Venlafaxine, SSRIs and TCAs

Cited by 54 publications

References 25 publications

Vagus Nerve Stimulation for Epilepsy and Depression

Vagus Nerve Stimulation for Epilepsy and Depression

A randomised controlled trial to compare the cost-effectiveness of tricyclic antidepressants, selective serotonin reuptake inhibitors and lofepramine

Pharmacoeconomics of antidepressants in moderate-to-severe depressive disorder in Colombia

Contact Info

Product

Resources

About